In the BioHarmony Drug Report Database
Filgotinib
Jyseleca (filgotinib) is a small molecule pharmaceutical. Filgotinib was first approved as Jyseleca on 2020-09-24. It has been approved in Europe to treat rheumatoid arthritis. The pharmaceutical is active against tyrosine-protein kinase JAK1. In addition, it is known to target tyrosine-protein kinase JAK3, non-receptor tyrosine-protein kinase TYK2, and tyrosine-protein kinase JAK2.
Trade Name
|
Jyseleca |
|---|---|
Common Name
|
filgotinib |
ChEMBL ID
|
CHEMBL3301607 |
Indication
|
rheumatoid arthritis |
Drug Class
|
Tyrosine kinase inhibitors |
Image (chem structure or protein)